Soluble immune checkpoint protein CD27 is a novel prognostic biomarker of HCC development in HCV-SVR patients.

[1]  Qing Zhao,et al.  Expression of CD28 in Hepatocellular Carcinoma and Its Prognostic Value , 2022, Hepatitis Monthly.

[2]  P. Pauwels,et al.  The CD70-CD27 axis in oncology: the new kids on the block , 2022, Journal of Experimental & Clinical Cancer Research.

[3]  A. Tamori,et al.  Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment , 2021, Scientific reports.

[4]  Guixiang Liao,et al.  Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2021, Frontiers in Oncology.

[5]  S. Ascani,et al.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy , 2021, Journal of personalized medicine.

[6]  E. Tartour,et al.  P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer , 2021, Journal for ImmunoTherapy of Cancer.

[7]  P. Nahon,et al.  Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control , 2021, Journal of clinical medicine.

[8]  M. Sho,et al.  Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[9]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[10]  G. Ioannou.  HCC surveillance after SVR in patients with F3/F4 fibrosis. , 2020, Journal of hepatology.

[11]  Xifeng Wu,et al.  Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study , 2020, Cancer Immunology, Immunotherapy.

[12]  A. Tamori,et al.  Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization , 2020, Cancers.

[13]  M. Giordano,et al.  Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics , 2020, Cancers.

[14]  A. Tamori,et al.  Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma , 2020, Scientific Reports.

[15]  R. Xiao,et al.  The Epigenetic Regulation of Scleroderma and Its Clinical Application. , 2020, Advances in experimental medicine and biology.

[16]  Y. Hosomi,et al.  High Serum Soluble CD27 Level Correlates with Poor Performance Status and Reduced Survival in Patients with Advanced Lung Cancer , 2019, Oncology.

[17]  V. Descalzi,et al.  Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[18]  N. Rothman,et al.  Circulating sCD27 and sCD30 in pre‐diagnostic samples collected fifteen years apart and future non‐Hodgkin lymphoma risk , 2019, International Journal of Cancer.

[19]  Xiang Xu,et al.  Soluble immune checkpoints in cancer: production, function and biological significance , 2018, Journal of Immunotherapy for Cancer.

[20]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[21]  G. Kristiansen,et al.  CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. , 2018, JCI insight.

[22]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[23]  H. Kato,et al.  Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells , 2018, Oncotarget.

[24]  J. Jang,et al.  Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling , 2018, Clinical and molecular hepatology.

[25]  R. D. de Knegt,et al.  Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. , 2017, Gastroenterology.

[26]  T. Nielsen,et al.  Emerging targets in cancer immunotherapy. , 2017, Seminars in cancer biology.

[27]  D. Lu,et al.  Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM , 2017, International journal of cancer.

[28]  T. Hassanein,et al.  Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. , 2017, The Lancet. Infectious diseases.

[29]  H. Saito,et al.  On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C , 2017, PloS one.

[30]  T. Bullock.  Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. , 2017, Current opinion in immunology.

[31]  R. Mohamed,et al.  CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. , 2017, Cellular immunology.

[32]  T. Pabst,et al.  CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia , 2017, The Journal of experimental medicine.

[33]  H. Gevensleben,et al.  PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients , 2017, Oncoimmunology.

[34]  M. Manns,et al.  Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. , 2016, The Journal of infectious diseases.

[35]  G. Freeman,et al.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.

[36]  R. D. de Knegt,et al.  Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. , 2016, The Journal of infectious diseases.

[37]  P. Pauwels,et al.  CD70: An emerging target in cancer immunotherapy. , 2015, Pharmacology & therapeutics.

[38]  P. V. Van Schil,et al.  Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer , 2015, Oncotarget.

[39]  C. Mu,et al.  Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis , 2015, Chronic diseases and translational medicine.

[40]  Chang Xian Li,et al.  Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway. , 2014, Cancer letters.

[41]  G. Kukolj,et al.  Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. , 2014, Journal of hepatology.

[42]  L. Prokunina-Olsson,et al.  Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. , 2014, The Journal of clinical investigation.

[43]  J. Ashwell,et al.  CD70 Is Downregulated by Interaction with CD27 , 2013, The Journal of Immunology.

[44]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[45]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[46]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[47]  M. Takemura,et al.  Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone , 2012, Leukemia & lymphoma.

[48]  K. Yoshizato,et al.  MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis , 2012, Gut.

[49]  Su Hyung Park,et al.  Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer , 2010, Molecules and cells.

[50]  I. Grewal.  Therapeutic targets of the TNF superfamily , 2009 .

[51]  G. Winberg,et al.  Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. , 2005, Experimental hematology.

[52]  Q. Lu,et al.  Demethylation of the Same Promoter Sequence Increases CD70 Expression in Lupus T Cells and T Cells Treated with Lupus-Inducing Drugs1 , 2005, The Journal of Immunology.

[53]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[54]  J. Hoofnagle,et al.  Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection1 , 2002, The Journal of Immunology.

[55]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[56]  R. V. van Lier,et al.  Expression and release of CD27 in human B-cell malignancies. , 1993, Blood.

[57]  W. Coley,et al.  Contribution To The Knowledge Of Sarcoma , 1891 .